Key result
ICARe-HF participation is linked to ~73% higher odds of quadruple therapy implementation in HFrEF.
Why the study?
The study aimed to assess differences in baseline characteristics, guideline-directed medical therapy implementation, and in-hospital outcomes between heart failure patients managed in centres participating or not in the ICARe-HF programme.
Does management in centres participating in the ICARe-HF programme improve guideline-directed medical therapy implementation and in-hospital mortality in heart failure patients?
Observational (n=10,936)
Yes
Does management in centres participating in the ICARe-HF programme improve guideline-directed medical therapy implementation and in-hospital mortality in heart failure patients?
Participation in a specialized accreditation programme (ICARe-HF) is associated with more comprehensive implementation of contemporary guideline-directed medical therapies in heart failure patients.
Background The Global Registries and Surveys Programme–Heart Failure (GRASP-HF) is a prospective, multicentre, international observational study assessing implementation of the 2021/2023 ESC-HF-Guidelines. GRASP-HF is aligned with the Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF) programme, which links centre-characteristics with guideline-implementation performance. Aims To compare baseline characteristics, guideline-directed-medical-therapy (GDMT) implementation, and in-hospital outcomes between GRASP-HF patients managed in centres participating or not participating in the ICARe-HF programme. Methods GRASP-HF patients were stratified by ICARe-HF participation, clinical settings, acute (AHF) vs chronic HF (CHF) and ejection fraction (EF) subtypes. Hierarchical multivariable logistic regression models evaluated associations with quadruple therapy implementation and in-hospital mortality. Results Among 10,936 patients (63.3% CHF, 36.7% AHF), patients from ICARe-HF participating centres (51.3%) were older, more comorbid but with less severe congestion. In both CHF and AHF, ICARe-HF centres demonstrated greater GDMT utilization, particularly angiotensin receptor–neprilysin inhibitors and sodium–glucose-cotransporter-2 inhibitors. In HFrEF, quadruple therapy was more frequently implemented (47% vs 40% in CHF; 27% vs 24% at AHF discharge) and remained associated with ICARe-HF participation after adjustment, Odd Ratio (OR) =1.73, 95% Confidence Interval (CI) :1.17–2.55. Target doses remained suboptimal, particularly after AHF. Although crude in-hospital mortality was lower in ICARe-HF centres (2.3% vs 5.5%), this association was attenuated after multivariable adjustment (OR=0.87, 95% CI:0.48–1.56). Conclusions Participation in the ICARe-HF programme was associated with more comprehensive implementation of contemporary GDMT, particularly in HFrEF. The association with in-hospital mortality was attenuated after adjustment and should be considered exploratory.
No takes yet. Share an insight, caveat, or question.
Chioncel et al. (2026) conducted an observational in Acute Hospitalized and Chronic Heart Failure (n=10,936). ICARe-HF programme participation vs. Non-ICARe-HF programme participation was evaluated on Quadruple therapy implementation in HFrEF (OR 1.73, 95% CI 1.17-2.55). Participation in the ICARe-HF programme was associated with greater quadruple therapy implementation in HFrEF (OR 1.73; 95% CI 1.17-2.55), but not significantly with lower in-hospital mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: